Table 2. Comparing Bcl-2 expression and prognostic parameters in NHL group.

Parameter		Bcl-2 positive		Bcl-2 negative		P	Significance
		N. cases	% cases	N. cases	% cases
Age (mean)	≥45 yrs	12	75	16	57.1	0.236	NS
	<45 yrs	4	25	12	42.9
Sex (mean)	M	10	62.5	16	57.1	0.728	NS
	F	6	37.5	12	42.9
Hb g/dL (mean)	≥10	8	50	14	50	1	NS
	<10	8	50	14	50
Plt ×109/L (mean)	≥150	4	25	22	78.6	0.001	HS
	<150	12	75	6	21.4
TLC ×109/L (mean)	≥8	8	50	6	21.4	0.052	NS
	<8	8	50	22	78.6
LDH IU/L (mean)	≥500	14	87.5	12	42.9	0.004	HS
	<500	2	12.5	16	57.1
Stage	I	0	0	6	21.4	0.239	NS
	II	2	12.5	4	14.3
	III	6	37.5	8	28.6
	IV	8	50	10	35.7
Pattern	Diffuse	4	25	2	7.2	0.36	NS
	Patchy	4	25	10	35.7
	Interstitial	2	12.5	6	21.4
	Mixed	6	37.5	10	35.7
Therapeutic	Responders	2	12.5	18	64.3	0.001	HS
response	Non-responders	14	87.5	10	35.7
Clinical	Complete remission	2	12.5	22	78.6	0.001	HS
outcome	Relapse	14	87.5	6	21.4
Fate	Alive	7	43.8	24	85.7	0.003	HS
	Death	9	56.2	4	14.3

S, significant; NS, non-significant; TLC, total leukocytic count; Hb, hemoglobin; Plts, platelets; BML, bone marrow lymphocytes; LDH, lactate dehydrogenase.